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Identiﬁ  cation of All 
Dengue Serotypes 
in Nepal 
To the Editor: Nepal is situ-
ated on the southern slopes of the 
Himalayas, surrounded by India on 3 
sides and China to the north. Nepal’s 
altitude ranges from 8,848 m in the 
Himalayas to 90 m in the Terai, the 
southern, low, ﬂ  atland bordering In-
dia. Nepal is a disease-endemic area 
for many vector-borne diseases, in-
cluding malaria, kala-azar, Japanese 
encephalitis, and lymphatic ﬁ  lariasis. 
Because of the porous border between 
Nepal and India, social, cultural, and 
economic activities in cross-border ar-
eas are common. 
Dengue is an emerging disease 
in Nepal; presumably transmission is 
moving north from India into the Terai 
(1–5). The ﬁ  rst report of dengue virus 
isolation or RNA (serotype 2 with nu-
cleotide homology closest to a dengue 
virus type 2 isolate from India) was 
in 2008 involving a  Japanese patient 
returning from Nepal in October 2004 
(5). Entomologic investigations from 
the 1980s showed Aedes albopictus in 
the Terai plains, but Ae. aegypti has 
not been previously reported.
After Indian outbreaks now 
known to include all 4 dengue sero-
types (6), a team from the Epidemi-
ology and Disease Control Division, 
Kathmandu, investigated suspected 
cases of dengue fever during Septem-
ber–October 2006 in Banke, the dis-
trict bordering Uttar Pradesh, India. 
The team collected blood samples 
from persons in Banke and, subse-
quently, from persons in a number 
of other districts and sent them to the 
National Public Health Laboratory in 
Kathmandu or the Armed Forces Re-
search Institute of Medical Sciences, 
Bangkok, Thailand for analysis with 
ELISA, reverse transcription–PCR, 
(RT-PCR), or both. 
Case deﬁ  nitions for dengue fever 
were adopted based on World Health 
Organization guidelines (7). Blood 
samples were obtained from patients 
with an acute febrile illness of 2–7 
days’ duration and with >2 of the 
following manifestations: headache, 
retro-orbital pain, muscular or joint 
pain, and rash. If laboratory tests were 
positive, cases were conﬁ  rmed.  Re-
sults were conﬁ  rmed by ELISA per-
formed at the Armed Forces Research 
Institute of Medical Sciences as pre-
viously described (8). Positive results 
were immunoglobulin (Ig) M >40 
units or IgG >100 units. RT-PCR was 
performed by extracting RNA from 
140 μL of each serum sample using 
QIAGEN Viral RNA Extraction Kit 
per manufacturer’s instructions (QIA-
GEN, Germantown, MD, USA). RT-
PCR and nested PCR were conducted 
according to the Lanciotti protocol 
(9) with the following modiﬁ  cations. 
Reverse transcriptase from avian my-
eloblastosis virus (Promega, Madi-
son, WI, USA) was used in the ﬁ  rst 
round RT-PCR. The concentrations of 
the primers used in the RT-PCR and 
nested reactions were reduced from 50 
pmol to 12.5 pmol per reaction, and 
the number of nested PCR ampliﬁ  ca-
tion cycles was increased to 25.
Serum specimens were obtained 
from 70 suspected case-patients from 
16 districts from October 13 through 
December 3, 2006; 25 conﬁ  rmed cas-
es (13 by ELISA, 10 by RT-PCR, and 
2 by both tests) came from 9 districts 
(Table). The average age was 29 years 
(range 5–65 years); 80% of the case-
patients were men. Three patients had 
a history of travel to India, but clus-
ters of dengue fever cases reported in 
October (Banke and Dang districts) 
indicated local transmission was oc-
curring among patients with no travel 
history. The Terai districts accounted 
for 80% of cases. Entomologic col-
lections done indoors and outside at 
5 different sites reporting suspected 
cases identiﬁ  ed Ae. albopictus and Ae. 
aegypti in all 5 districts. 
These clinical and laboratory test 
results conﬁ  rmed the presence of all 
4 dengue serotypes. Notably, patients 
from the Dang district had no travel 
history outside the Dang valley. Be-
cause Aedes spp. have been identiﬁ  ed 
in Dang, the data strongly suggest 
the existence of an endemic cycle of 
dengue. Underreporting is expected 
in the absence of diagnostic facilities 
at the ﬁ  eld level. It is unclear whether 
the predominance of male patients is 
indicative of greater outdoor as op-
posed to indoor transmission. Of note, 
Ae. albopictus has been found in the 
country since the 1980s; in this study, 
we found Ae. aegypti in Nepal. Men 
typically wear short-sleeved clothes 
due to hot and humid conditions and, 
therefore, are frequently exposed to 
mosquito bites. However, men may 
also access the healthcare system 
more frequently. The ages of case-pa-
tients point to a relative lack of dengue 
immunity among the older population, 
and this ﬁ  nding is consistent with a 
new introduction of dengue. Because 
dengue hemorrhagic fever appears 
when >1 serotype becomes endemic 
to an area (10), the presence of all 4 
serotypes portends the emergence of 
more severe dengue disease in Nepal. 
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Table. Dengue laboratory test results, National Public Health Laboratory, Nepal, and AFRIMS, Bangkok, 2006* 
Patient no.  Age, y  Gender  Residence Travel history  ELISA RT-PCR 
1 39 M Kathmandu Unknown Positive DEN-3
2 48 M Banke Yes Negative DEN-3
3 18 M Banke No Negative DEN-3
4 20 M Banke No Negative DEN-3
5 22 M Banke No Negative DEN-3
6 25 M Banke No Negative DEN-3
7 25 M Kathmandu Unknown Negative DEN-1
8 26 F Kathmandu Unknown Positive DEN-3
9 38 M Parsa No Negative DEN-4
10 16 M Dhading Unknown Negative DEN-2
11 25 M Jhapa No Positive ND
12 37 F Parsa Unknown Positive ND
13 38 M Dhading No Positive ND
14 24 M Banke No Positive ND
15 36 M Banke No Positive ND
16 22 M Parsa Unknown Positive ND
17 5 F Rupandehi No Positive ND
18 13 M Dang No Positive ND
19 35 F Parsa No Positive ND
20 20 M Kathmandu Yes Positive ND
21 40 M Kapilbastu No Positive ND
22 20 F Rupandehi No Positive ND
23 42 M Dang No Positive ND
24 65 M Banke Yes Positive ND
25 28 M Dang No Positive ND
*AFRIMS, Armed Forces Research Institute of Medical Sciences; RT-PCR, reverse transcription–PCR; DEN, dengue; ND, not done. 